Turn Therapeutics Inc. (NASDAQ:TTRX) Stock Has Average Target Price of $9.00

Shares of Turn Therapeutics Inc. (NASDAQ:TTRX) have earned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $9.00.

A number of brokerages have commented on TTRX. Weiss Ratings lowered shares of Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 18th. Zacks Research upgraded shares of Turn Therapeutics to a “hold” rating in a report on Tuesday, July 21st. LADENBURG THALM/SH SH raised shares of Turn Therapeutics to a “strong-buy” rating in a research note on Monday, July 20th. WBB Securities reaffirmed a “sell” rating and issued a $10.00 price objective on shares of Turn Therapeutics in a research note on Monday, September 14th. Finally, Lucid Cap Mkts upgraded shares of Turn Therapeutics to a “strong-buy” rating in a report on Thursday, September 24th.

Institutional Investors Weigh In On Turn Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in TTRX. Bank of America Corp DE bought a new position in Turn Therapeutics in the 2nd quarter valued at about $103,000. Tamar Securities LLC bought a new stake in Turn Therapeutics during the 4th quarter worth approximately $59,000. Jefferies Financial Group Inc. bought a new stake in Turn Therapeutics during the 2nd quarter worth approximately $119,000. Bridgewater Advisors Inc. bought a new stake in Turn Therapeutics during the 2nd quarter worth approximately $242,000. Finally, BlackRock Inc. purchased a new stake in shares of Turn Therapeutics in the second quarter worth approximately $282,000.

Turn Therapeutics Stock Performance

NASDAQ TTRX opened at $12.00 on Friday. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 8.83. Turn Therapeutics has a 52 week low of $2.57 and a 52 week high of $16.45. The business has a 50 day moving average price of $11.46 and a 200-day moving average price of $7.66. The company has a market cap of $357.48 million and a price-to-earnings ratio of -41.38.

Turn Therapeutics (NASDAQ:TTRX) last issued its earnings results on Wednesday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter. As a group, equities analysts expect that Turn Therapeutics will post -0.40 earnings per share for the current fiscal year.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.